Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit

Bottaro, 1991, Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product, Science, 251, 802, 10.1126/science.1846706 Zhang, 2003, HGF/SF-met signaling in the control of branching morphogenesis and invasion, J Cell Biochem, 88, 408, 10.1002/jcb.10358 Boccaccio, 2006, Invasive growth: a MET-driven genetic programme for cancer and stem cells, Nat Rev Cancer, 6, 637, 10.1038/nrc1912 Christensen, 2005, c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention, Cancer Lett, 225, 1, 10.1016/j.canlet.2004.09.044 Danilkovitch-Miagkova, 2002, Dysregulation of Met receptor tyrosine kinase activity in invasive tumors, J Clin Invest, 109, 863, 10.1172/JCI0215418 Lemmon, 2010, Cell signaling by receptor tyrosine kinases, Cell, 141, 1117, 10.1016/j.cell.2010.06.011 Blumenschein, 2012, Targeting the hepatocyte growth factor-cMET axis in cancer therapy, J Clin Oncol, 30, 3287, 10.1200/JCO.2011.40.3774 Schmidt, 1997, Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas, Nat Genet, 16, 68, 10.1038/ng0597-68 Olivero, 1999, Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family, Int J Cancer, 82, 640, 10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6 Ma, 2003, c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions, Cancer Res, 63, 6272 Graveel, 2004, Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele, Proc Natl Acad Sci U S A, 101, 17198, 10.1073/pnas.0407651101 Ma, 2005, Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer, Cancer Res, 65, 1479, 10.1158/0008-5472.CAN-04-2650 Houldsworth, 1990, Gene amplification in gastric and esophageal adenocarcinomas, Cancer Res, 50, 6417 Tong, 2004, Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization, J Neurosurg, 100, 187, 10.3171/ped.2004.100.2.0187 Beroukhim, 2007, Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma, Proc Natl Acad Sci U S A, 104, 20007, 10.1073/pnas.0710052104 Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478 Smolen, 2006, Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752, Proc Natl Acad Sci U S A, 103, 2316, 10.1073/pnas.0508776103 Zeng, 2008, c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases, Cancer Lett, 265, 258, 10.1016/j.canlet.2008.02.049 Tsugawa, 1998, Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features, Oncology, 55, 475, 10.1159/000011898 Beviglia, 1997, Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression, Int J Cancer, 74, 301, 10.1002/(SICI)1097-0215(19970620)74:3<301::AID-IJC12>3.0.CO;2-E Hochgrafe, 2010, Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells, Cancer Res, 70, 9391, 10.1158/0008-5472.CAN-10-0911 Gastaldi, 2010, The Met oncogene and basal-like breast cancer: another culprit to watch out for?, Breast Cancer Res, 12, 208, 10.1186/bcr2617 Lengyel, 2005, C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu, Int J Cancer, 113, 678, 10.1002/ijc.20598 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Tengs, 2006, A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing, Cancer Lett, 239, 227, 10.1016/j.canlet.2005.08.007 Bardelli, 2013, Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer, Cancer Discov, 3, 658, 10.1158/2159-8290.CD-12-0558 Straussman, 2012, Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion, Nature, 487, 500, 10.1038/nature11183 Shojaei, 2010, HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors, Cancer Res, 70, 10090, 10.1158/0008-5472.CAN-10-0489 Nielsen, 2004, Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma, Clin Cancer Res, 10, 5367, 10.1158/1078-0432.CCR-04-0220 Rakha, 2008, Basal-like breast cancer: a critical review, J Clin Oncol, 26, 2568, 10.1200/JCO.2007.13.1748 Graveel, 2009, Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer, Proc Natl Acad Sci U S A, 106, 12909, 10.1073/pnas.0810403106 Ponzo, 2009, Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer, Proc Natl Acad Sci U S A, 106, 12903, 10.1073/pnas.0810402106 Inanc, 2014, Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer, Med Oncol, 31, 801, 10.1007/s12032-013-0801-7 Sierra, 2011, c-MET as a potential therapeutic target and biomarker in cancer, Ther Adv Med Oncol, 3, S21, 10.1177/1758834011422557 Paulson, 2013, MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance, Mol Cancer Res, 11, 1112, 10.1158/1541-7786.MCR-13-0042 Minuti, 2012, Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer, Br J Cancer, 107, 793, 10.1038/bjc.2012.335 Raghav, 2012, cMET and phospho-cMET protein levels in breast cancers and survival outcomes, Clin Cancer Res, 18, 2269, 10.1158/1078-0432.CCR-11-2830 Ai, 2010, Zhonghua Zhong Liu Za Zhi, 32, 825